 |
|
Chelation Therapy for Ischemic Heart Disease
A Randomized Controlled Trial
Merril L. Knudtson, MD;
D. George Wyse, MD,PhD;
P. Diane Galbraith, BN;
Rollin Brant, PhD;
Kathy Hildebrand, BN;
Diana Paterson, BScN;
Deborah Richardson, RN;
Connie Burkart, BN;
Ellen Burgess, MD;
for the Program to Assess Alternative Treatment Strategies to Achieve Cardiac Health (PATCH) Investigators
JAMA. 2002;287:481-486.
Context Chelation therapy using EDTA is an unproven but widely used alternative therapy for ischemic heart disease.
Objective To determine if current EDTA protocols have a favorable impact on exercise ischemia threshold and quality of life measures in patients with stable ischemic heart disease.
Design Double-blind, randomized, placebo-controlled trial conducted between January 1996 and January 2000.
Setting Participants were recruited from a cohort of cardiac catheterization patients and the practices of cardiologists in Calgary, Alberta.
Participants We screened 3140 patients, performed a qualifying treadmill test in 171, and enrolled 84. Entry criteria included age at least 21 years with coronary artery disease proven by angiography or a documented myocardial infarction and stable angina while receiving optimal medical therapy. The required treadmill test used a gradual ramping protocol and patients had to demonstrate at least 1-mm ST depression.
Interventions Patients were randomly assigned to receive infusion with either weight-adjusted (40 mg/kg) EDTA chelation therapy (n = 41) or placebo (n = 43) for 3 hours per treatment, twice weekly for 15 weeks and once per month for an additional 3 months. Patients in both groups took oral multivitamin therapy as well.
Main Outcome Measure Change from baseline to 27-week follow-up in time to ischemia (1-mm ST depression).
Results Thirty-nine patients in each group completed the 27-week protocol. One chelation patient had therapy discontinued for a transient rise in serum creatinine. The mean (SD) baseline exercise time to ischemia was 572 (172) and 589 (176) seconds in the placebo and chelation groups, respectively. The corresponding mean changes in time to ischemia at 27 weeks were 54 seconds (95% confidence interval [CI], 23-84 seconds; P<.001) and 63 seconds (95% CI, 29-95 seconds; P<.001), for a difference of 9 seconds (95% CI, -36 to 53 seconds; P = .69). Exercise capacity and quality of life scores improved by similar degrees in both groups.
Conclusion Based on exercise time to ischemia, exercise capacity, and quality of life measurements, there is no evidence to support a beneficial effect of chelation therapy in patients with ischemic heart disease, stable angina, and a positive treadmill test for ischemia.
Author Affiliations: Division of Cardiology, University of Calgary and Calgary Regional Health Authority, Calgary, Alberta.
RELATED ARTICLE
January 23/30, 2002
JAMA. 2002;287(4):527-528.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Additional Information
JAMA 2006;295:E1-E6.
FULL TEXT
Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy
Anderson et al.
J Am Coll Cardiol 2003;41:420-425.
ABSTRACT
| FULL TEXT
Chelation Is Ineffective for Coronary Artery Disease
JWatch Emergency Med. 2002;2002:11-11.
FULL TEXT
Chelation Therapy for Patients With Ischemic Heart Disease
Bell et al.
JAMA 2002;287:2077-2078.
FULL TEXT
No Benefit of Chelation Therapy in CAD Patients
Journal Watch Cardiology 2002;2002:2-2.
FULL TEXT
Refractory angina pectoris: Mechanism and therapeutic options
Kim et al.
J Am Coll Cardiol 2002;39:923-934.
ABSTRACT
| FULL TEXT
Chelation Therapy Not Beneficial in Coronary Disease
JWatch Gastroenterology 2002;2002:12-12.
FULL TEXT
Chelation Therapy Not Beneficial in Coronary Disease
JWatch General 2002;2002:3-3.
FULL TEXT
|
